Monitor for follow-up filings or commentary around corporate performance; repeated C-suite selling could signal weakening confidence, especially if not part of a pre-arranged 10b5-1 plan. Check upcoming earnings date and recent stock performance for context.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 27 $13.67entry
- T+1 · 9mo ago −1.10%α −1.15% · $13.52
- T+5 · 9mo ago −4.61%α −2.63% · $13.04
- T+20 · 8mo ago −19.75%α −12.20% · $10.97
- T+60 · 6mo ago +33.58%α +24.19% · $18.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple NovoCure executives, including CEO Leonard Frank X and Chief Medical Officer Uri Weinberg, conducted open-market share sales over a 7-day period, totaling approximately $434,000 in gross proceeds. These sales were accompanied by non-cash grant and tax withholding events involving former and current executives. The selling activity represents modest insider divestment by senior leaders.
Key Financial Metrics
Key Facts
- CEO Leonard Frank X sold 16,966 shares for $230,584.81 in open-market transactions.
- Chief Medical and Innovation Officer Uri Weinberg sold 10,733 shares for $146,863.44.
- COO Mukund and CHRO Puri also sold shares, totaling $26,752.35 and $19,689.54 respectively.
- Total open-market sales by insiders: 32,851 shares for ~$434,000.
- Tax withholding events (non-cash) for former CEO Cordova totaled ~$191,633.
- All share grants (totaling over 73,000 shares) were non-cash awards with $0 transaction value.
- Total insider selling represents ~0.029% of $1.5B market cap, modest but notable given concentration among C-suite.
Financial Impact
$434,000 in open-market insider selling over 7 days
Risk Factors
- Perception of insider pessimism given participation by CEO and top medical officer.
- Lack of offsetting open-market purchases increases bearish interpretation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (13 trades, 7d window) | cluster-NVCR-1772574379465 |
Track record
20 reports on NVCR
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +14.32% at T+5 after the Jun 30, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers